Log in Join free

Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2−metastatic breast cancer

T. Önder Öztürk Ateş

Aug 2026 · Breast Cancer · Vol 33, pp. 1214 - 1226 · 0 citations · 24 references

Medicine

DOI PubMed Semantic Scholar

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.